Applications open for AI-Enabled COVID-19 Treatment Research Grant

Pfizer has launched a competitive research grant program to support projects that use artificial intelligence (AI) and advanced clinical decision support (CDS) systems to improve timely and safe access to nirmatrelvir/ritonavir treatment for eligible COVID-19 patients. Individual research projects can receive up to USD 500,000 for a maximum duration of two years, with funding available to eligible organizations in selected countries.

About the Pfizer AI Research Grant Program

Pfizer is inviting research proposals that leverage artificial intelligence (AI) and advanced clinical decision support technologies to improve the delivery of outpatient COVID-19 antiviral treatment.

The program aims to address barriers that prevent eligible patients from receiving nirmatrelvir/ritonavir within the recommended treatment window. Successful projects should develop innovative solutions that help healthcare providers identify eligible patients quickly, manage potential drug–drug interactions (DDIs), and improve treatment outcomes.

The initiative supports evidence-based research that combines healthcare innovation, digital health technologies, and clinical decision-making to improve patient care.

Funding Overview

The Pfizer AI Research Grant provides financial support for eligible research projects.

Funding Details

Maximum funding per project: USD 500,000
Maximum project duration: 2 years
Funding is awarded on a competitive basis.
Only research projects meeting the eligibility criteria will be considered.

Programme Objectives

The grant program aims to:

Improve timely access to COVID-19 antiviral treatment.
Increase safe prescribing of nirmatrelvir/ritonavir.
Support the use of artificial intelligence in healthcare.
Enhance clinical decision support systems.
Improve patient eligibility assessment.
Reduce treatment delays.
Improve management of drug–drug interactions.
Strengthen outpatient COVID-19 care.

Focus Areas

Projects should address one or more of the following priorities:

Artificial Intelligence in Healthcare

Research may include:

AI-powered patient identification.
Predictive clinical algorithms.
Machine learning for treatment eligibility.
Automated clinical risk assessment.

Clinical Decision Support

Projects may develop:

Advanced clinical decision support tools.
Electronic prescribing support.
Integrated healthcare workflows.
Clinical alert systems.

Patient Eligibility Assessment

Research should improve:

Identification of eligible COVID-19 patients.
Use of current clinical guidelines.
Clinical data integration.
Rapid treatment decision-making.

Drug–Drug Interaction (DDI) Management

Projects are encouraged to develop solutions that:

Identify clinically significant drug–drug interactions.
Reduce medication-related risks.
Support safer antiviral prescribing.
Improve medication management.

Why Early COVID-19 Antiviral Treatment Matters

Early treatment plays a critical role in reducing severe outcomes among high-risk COVID-19 patients.

Starting nirmatrelvir/ritonavir within five days of symptom onset can help:

Reduce hospitalization.
Lower the risk of severe illness.
Decrease COVID-19-related mortality.
Improve patient recovery.
Enhance healthcare outcomes.

AI-enabled clinical tools can help ensure eligible patients receive treatment within this important therapeutic window.

What Types of Projects Are Supported?

Eligible research projects may include:

AI-based eligibility screening.
Clinical decision support software.
Drug–drug interaction management systems.
Digital health technologies.
Healthcare workflow improvements.
Outpatient treatment optimization.
Clinical implementation research.
Health informatics solutions.

Projects should address barriers to delivering timely outpatient antiviral therapy.

Who Is Eligible?

Only organizations may apply for funding.

Eligible organizations must be based in one of the following countries:

Both the organization and the proposed Principal Investigator (PI) must satisfy Pfizer’s eligibility requirements.

Principal Investigator Eligibility

The Principal Investigator must hold one of the following qualifications:

Medical degree.
Postdoctoral degree.
Advanced nursing degree.
Pharmacy degree.
Physiotherapy degree.
Social Work degree.

The PI must also:

Be employed by or contracted to the applicant organization.
Lead the proposed research project.
Meet all Pfizer eligibility requirements.

Organizational Requirements

The applicant organization must:

Be legally established.
Be legally able to receive funding directly from Pfizer Inc.
Meet all applicable legal and administrative requirements.
Employ or contract the proposed Principal Investigator.

Only organizations—not individuals—are eligible to receive grant funding.

Expected Project Outcomes

Successful projects should demonstrate:

Faster identification of eligible patients.
Improved antiviral prescribing.
Better management of drug–drug interactions.
Increased adherence to treatment guidelines.
Enhanced patient safety.
Improved clinical outcomes.
Greater use of AI in healthcare delivery.

Projects should produce practical solutions that can improve outpatient COVID-19 care.

Why This Grant Matters

Artificial intelligence has the potential to transform healthcare by improving clinical decision-making and reducing treatment delays.

This Pfizer funding opportunity supports innovations that can:

Improve patient access to life-saving treatment.
Reduce healthcare system burden.
Enhance medication safety.
Support clinicians in complex prescribing decisions.
Improve health outcomes for high-risk COVID-19 patients.
Advance digital healthcare innovation.

How to Apply

Applicants should follow these general steps:

Confirm that your organization is located in an eligible country.
Verify that both the organization and Principal Investigator meet Pfizer’s eligibility requirements.
Identify a research challenge related to outpatient COVID-19 antiviral treatment.
Develop an AI-enabled or clinical decision support research proposal.
Explain how the project will improve treatment eligibility assessment or drug–drug interaction management.
Prepare a detailed project timeline and budget.
Ensure the proposed funding request does not exceed USD 500,000 and the project duration does not exceed two years.
Submit the proposal according to Pfizer’s official grant application process.

Tips for a Strong Application

To improve your chances of success:

Clearly define the clinical problem.
Demonstrate the innovative use of AI.
Explain expected patient outcomes.
Show alignment with current COVID-19 treatment guidelines.
Include measurable project objectives.
Present a realistic implementation plan.
Demonstrate multidisciplinary collaboration.
Provide a well-justified budget.

Common Mistakes to Avoid

Avoid these common application errors:

Applying as an individual rather than an eligible organization.
Exceeding the maximum funding amount.
Proposing projects longer than two years.
Failing to explain the AI component.
Ignoring drug–drug interaction management.
Providing unclear clinical outcomes.
Submitting incomplete eligibility documentation.
Proposing projects outside the program’s focus areas.

Frequently Asked Questions (FAQs)

1. What is the Pfizer AI Research Grant Program?

It is a competitive funding opportunity supporting research projects that use artificial intelligence and advanced clinical decision support solutions to improve access to nirmatrelvir/ritonavir treatment for eligible COVID-19 patients.

2. How much funding is available?

Individual projects may request up to USD 500,000 for a maximum project duration of two years.

3. Who can apply?

Only eligible organizations located in Australia, Canada, Germany, Greece, Japan, Korea, or Taiwan may apply. Individuals cannot receive funding directly.

4. What types of projects are eligible?

Eligible projects include AI-enabled eligibility assessment, clinical decision support systems, drug–drug interaction management tools, digital health innovations, and outpatient COVID-19 treatment improvement initiatives.

5. Who can serve as the Principal Investigator?

The PI must hold a medical, postdoctoral, advanced nursing, pharmacy, physiotherapy, or social work degree and be employed by or contracted to the applicant organization.

6. Why is early antiviral treatment important?

Initiating nirmatrelvir/ritonavir within five days of symptom onset can significantly reduce the risk of severe illness, hospitalization, and death among high-risk COVID-19 patients.

7. What makes a competitive proposal?

Strong proposals demonstrate innovative AI applications, robust clinical relevance, effective drug–drug interaction management, measurable patient outcomes, realistic implementation plans, and clear alignment with the program’s objectives.

Conclusion

The Pfizer AI Research Grant Program offers up to USD 500,000 to support innovative research that improves timely and safe access to COVID-19 antiviral treatment through artificial intelligence and advanced clinical decision support. By funding projects that enhance patient eligibility assessment, optimize drug–drug interaction management, and strengthen outpatient care, the program seeks to advance digital health innovation and improve clinical outcomes for high-risk COVID-19 patients worldwide.